# TODO Organization Report

Generated: 2026-01-06

## Summary

| Metric | Count |
|--------|------:|
| Total actionable items | 47 |
| Chapters covered | 11 (Ch10-Ch20) |
| Chapters with NO notes | 18 (Ch1-9, Ch21-29) |

### By Priority
| Priority | Count |
|----------|------:|
| High (affects accuracy/flow) | 12 |
| Medium (clarity/structure) | 23 |
| Low (polish/style) | 12 |

### By Type
| Type | Count |
|------|------:|
| Cross-reference | 8 |
| Structure | 7 |
| Clarity | 11 |
| Content | 10 |
| Citation | 4 |
| Verification | 5 |
| Style | 2 |

## High Priority Items

| Ch | Type | Description | Line |
|----|------|-------------|-----:|
| 12 | Verification | Validate if ESMFold is MSA-free; clarify AlphaFold single-seq capability | 90 |
| 13 | Content | Add sidebar on regulatory genomics experimental assays (ChIP-seq, ATAC-seq, Hi-C, STARR-seq) | 119 |
| 14 | Content | Add ACMG sidebar summarizing clinical variant interpretation guidelines | 184 |
| 14 | Cross-ref | Ensure uncertainty section doesn't repeat Ch23; x-ref as primary source | 187 |
| 14 | Content | Add deep dive on zero-shot likelihood calculations (masked marginal, pseudolikelihood, etc.) | 163 |
| 11 | Cross-ref | X-ref benchmark details to Ch20 (this chapter should summarize, Ch20 has details) | 60-62 |
| 11 | Cross-ref | X-ref practical usage sections to Ch5-9 as primary source | 66 |
| 13 | Clarity | Terminology inconsistency: "regulatory model" vs "sequence-to-function model" | 117 |
| 10 | Citation | Add variant scaling paper (biorxiv 2025.10.26.684578v1) | 12 |
| 12 | Content | Explain BFD dataset origin (AlphaFold?) and purpose | 82 |
| 12 | Content | Better explain T5 and XLNet differences from BERT | 83 |
| 14 | Clarity | Clarify terms: "calibration set", "prediction set", "single-element sets" | 190 |

## Items by Chapter

### Chapter 10: Foundation Model Paradigm
| Type | Description | Line |
|------|-------------|-----:|
| Citation | Add variant scaling paper | 12 |
| Structure | Design Dimensions subsections too brief (1 paragraph each) | 22 |
| Clarity | "Build Versus Use Decisions" title is ambiguous | 28 |

### Chapter 11: DNA Language Models
| Type | Description | Line |
|------|-------------|-----:|
| Clarity | Give specific model examples for MLM vs autoregressive (in intro paragraph) | 47 |
| Cross-ref | X-ref benchmark section to Ch20 for details | 60 |
| Content | Move benchmark suite details to Ch20, keep summaries here | 62 |
| Cross-ref | X-ref "Using DNA LMs in Practice" to Ch5-9 | 66 |

### Chapter 12: Protein Language Models
| Type | Description | Line |
|------|-------------|-----:|
| Style | Consider dropping corporate names ("Meta AI Research") | 76 |
| Content | ESM-2 table not helpful as-is; consider removing | 80 |
| Content | Explain BFD dataset origin and purpose | 82 |
| Content | Better explain T5/XLNet differences from BERT | 83 |
| Clarity | Explain SE(3) equivariant or drop group theory term | 89 |
| Verification | Validate ESMFold MSA-free claim; clarify AlphaFold capabilities | 90 |
| Clarity | Mention AlphaFold crystal template usage | 90 |
| Content | Don't repeat sidebar content outside sidebar | 91 |
| Style | Drop meta-commentary like "this book" | 92 |
| Clarity | Break up long sentence in Function Prediction intro | 95 |
| Structure | Limitations subsections too brief (1 paragraph each) | 99 |

### Chapter 13: Regulatory Models
| Type | Description | Line |
|------|-------------|-----:|
| Clarity | Confusing paragraph about kilobase windows | 115 |
| Clarity | Inconsistent terminology: "regulatory model" vs "sequence-to-function" | 117 |
| Content | **HIGH** Add sidebar on regulatory genomics assays | 119 |
| Verification | Validate attention scaling repetition is appropriate here | 123 |
| Content | Note that AlphaGenome API doesn't provide embeddings | 138 |

### Chapter 14: Variant Effect Prediction
| Type | Description | Line |
|------|-------------|-----:|
| Citation | Cite CADD in intro | 156 |
| Clarity | Replace "developers" with "researchers" or "model builders" | 157 |
| Verification | Check "billions of substitutions / millions of years" → should be trillions/billions? | 160 |
| Cross-ref | Don't repeat Ch12/Ch9 on zero-shot; x-ref those chapters | 162 |
| Content | **HIGH** Add sidebar on zero-shot likelihood calculations | 163 |
| Clarity | Clarify which PLM AlphaMissense uses | 166 |
| Cross-ref | Reference ACMG mapping (14.5.3) when discussing SpliceAI clinical categories | 169 |
| Cross-ref | Reference ACMG (14.5.3) in double-counting section | 176 |
| Content | Select specific models from Pejaver et al for ACMG mapping discussion | 182 |
| Content | **HIGH** Add ACMG sidebar for clinical variant interpretation | 184 |
| Cross-ref | Ensure uncertainty section doesn't repeat Ch23 | 187 |
| Clarity | Clarify "calibration set", "prediction set" terminology | 190 |
| Clarity | Define "low embedding density" | 192 |
| Citation | Cite "better performance" claim | 195 |
| Clarity | Fix awkward 3-parenthetical-questions paragraph in Lab Validation | 201 |
| Clarity | "Training data composition determines..." is clunky | 210 |
| Clarity | "diverse urban" may be misinterpreted; use "cosmopolitan" or "heterogeneous" | 211 |

### Chapters 15-20: No Specific Action Items
Notes file contains section headers but no actionable items for these chapters.

## Items by Type

### Cross-Reference Issues (8 items)
| Chapter | Description |
|---------|-------------|
| Ch11 | X-ref benchmark details → Ch20 |
| Ch11 | X-ref practical usage → Ch5-9 |
| Ch14 | X-ref zero-shot → Ch12, Ch9 |
| Ch14 | X-ref SpliceAI clinical → §14.5.3 ACMG |
| Ch14 | X-ref double-counting → §14.5.3 ACMG |
| Ch14 | X-ref uncertainty → Ch23 |

### Structure Issues (7 items)
| Chapter | Description |
|---------|-------------|
| Ch10 | Design Dimensions subsections too brief |
| Ch12 | Limitations subsections too brief |
| Ch12 | Sidebar content repeated outside sidebar |

### Clarity Issues (11 items)
| Chapter | Description |
|---------|-------------|
| Ch10 | "Build Versus Use" title ambiguous |
| Ch11 | Need specific MLM vs autoregressive examples |
| Ch12 | SE(3) equivariant needs explanation |
| Ch12 | Long sentence in Function Prediction |
| Ch13 | Confusing kilobase windows paragraph |
| Ch13 | "regulatory model" vs "sequence-to-function" inconsistency |
| Ch14 | Replace "developers" terminology |
| Ch14 | Clarify PLM used by AlphaMissense |
| Ch14 | Clarify calibration terminology |
| Ch14 | Define "low embedding density" |
| Ch14 | Awkward Lab Validation paragraph |
| Ch14 | "Training data composition..." clunky |
| Ch14 | "diverse urban" potentially confusing |

### Content Gaps (10 items)
| Chapter | Description | Priority |
|---------|-------------|----------|
| Ch13 | Regulatory assays sidebar | **HIGH** |
| Ch14 | ACMG guidelines sidebar | **HIGH** |
| Ch14 | Zero-shot likelihood calculations deep dive | **HIGH** |
| Ch12 | BFD dataset explanation | Medium |
| Ch12 | T5/XLNet vs BERT explanation | Medium |
| Ch12 | ESM-2 table removal or improvement | Low |
| Ch13 | AlphaGenome API embeddings note | Low |
| Ch14 | Pejaver model selection | Medium |

### Citations Needed (4 items)
| Chapter | Description |
|---------|-------------|
| Ch10 | Variant scaling paper |
| Ch14 | CADD in intro |
| Ch14 | "better performance" claim |

### Verification Needed (5 items)
| Chapter | Description |
|---------|-------------|
| Ch12 | ESMFold MSA-free claim |
| Ch12 | AlphaFold single-sequence capability |
| Ch13 | Attention scaling repetition appropriate? |
| Ch14 | "billions/millions" → "trillions/billions"? |

## Suggested Work Sessions

### Session 1: Part 3 Cross-References (Ch10-14)
Focus: Reduce redundancy, add proper cross-references
- [ ] Ch11: Add x-refs to Ch20 for benchmark details
- [ ] Ch11: Add x-refs to Ch5-9 for practical usage
- [ ] Ch14: Add x-refs to Ch23 for uncertainty
- [ ] Ch14: Add internal x-refs to §14.5.3 ACMG mapping
- [ ] Ch14: Add x-refs to Ch12/Ch9 for zero-shot

### Session 2: High-Priority Content Additions
Focus: Add missing sidebars and deep dives
- [ ] Ch13: Write regulatory assays sidebar (ChIP-seq, ATAC-seq, Hi-C, STARR-seq)
- [ ] Ch14: Write ACMG guidelines sidebar
- [ ] Ch14: Write zero-shot likelihood calculations sidebar

### Session 3: Chapter 12 Cleanup
Focus: Technical accuracy and clarity
- [ ] Validate ESMFold MSA-free claim
- [ ] Clarify AlphaFold single-sequence + template capabilities
- [ ] Explain SE(3) or simplify
- [ ] Explain BFD dataset
- [ ] Explain T5/XLNet vs BERT
- [ ] Decide on ESM-2 table fate

### Session 4: Chapter 14 Polish
Focus: Clarity and terminology
- [ ] Clarify AlphaMissense PLM
- [ ] Fix calibration terminology
- [ ] Define "low embedding density"
- [ ] Fix awkward sentences (Lab Validation, Training data, diverse urban)
- [ ] Add citations (CADD, performance claims)

### Session 5: Brief Sections Expansion
Focus: Flesh out stub sections
- [ ] Ch10: Expand Design Dimensions subsections
- [ ] Ch12: Expand Limitations subsections

## Recurring Patterns

### 1. Cross-Reference Debt
Multiple chapters explain the same concepts:
- **Zero-shot prediction**: Ch9, Ch11, Ch12, Ch14
- **Benchmarks**: Ch11, Ch20
- **Uncertainty quantification**: Ch14, Ch23
- **ACMG guidelines**: Ch14, Ch26

**Action**: Designate "source of truth" chapters; others should x-ref.

### 2. Brief Subsections
Pattern of 1-paragraph subsections appears in:
- Ch10 Design Dimensions
- Ch12 Limitations

**Action**: Either expand these or consolidate into fewer, more substantial sections.

### 3. Missing Sidebars
Two high-value sidebars identified:
- Regulatory genomics assays (Ch13)
- ACMG clinical guidelines (Ch14)

**Action**: Prioritize these for next content sprint.

### 4. Terminology Inconsistency
- "regulatory model" vs "sequence-to-function model"
- "developers" vs "researchers" vs "model builders"

**Action**: Create terminology reference; do find-replace pass.

## Coverage Gap

**Chapters with detailed notes**: 10, 11, 12, 13, 14 (Part 3 focus)
**Chapters with headers only**: 15, 16, 17, 18, 19, 20
**Chapters with NO notes**: 1-9, 21-29

The TODO file heavily focuses on Part 3. Parts 1, 2, 5, and 6 need similar review passes.
